PMS-PANTOPRAZOLE TABLET (DELAYED-RELEASE)

Šalis: Kanada

kalba: anglų

Šaltinis: Health Canada

Veiklioji medžiaga:

PANTOPRAZOLE (PANTOPRAZOLE SODIUM)

Prieinama:

PHARMASCIENCE INC

ATC kodas:

A02BC02

INN (Tarptautinis Pavadinimas):

PANTOPRAZOLE

Dozė:

40MG

Vaisto forma:

TABLET (DELAYED-RELEASE)

Sudėtis:

PANTOPRAZOLE (PANTOPRAZOLE SODIUM) 40MG

Vartojimo būdas:

ORAL

Vienetai pakuotėje:

100/500

Recepto tipas:

Prescription

Gydymo sritis:

PROTON-PUMP INHIBITORS

Produkto santrauka:

Active ingredient group (AIG) number: 0133229001; AHFS:

Autorizacija statusas:

APPROVED

Leidimo data:

2008-06-03

Prekės savybės

_pms-PANTOPRAZOLE _
_Page 1 of 53_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
PMS-PANTOPRAZOLE
Pantoprazole Sodium
Delayed-Release Tablets, 20 mg and 40 mg, Oral
House Standard (20 mg) & USP (40 mg)
Proton Pump Inhibitor
PHARMASCIENCE INC.
6111 Royalmount Ave., Suite 100
Montréal, Québec
H4P 2T4
www.pharmascience.com
Submission Control Number:
275567
Date of Initial Authorization:
FEB 7, 2007
Date of Revision:
SEP 19, 2023
_pms-PANTOPRAZOLE _
_Page 2 of 53_
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS, Immune
05/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
...........................................................................................
2
TABLE OF CONTENTS
.............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
1
INDICATIONS
...................................................................................................................
4
1.1
Pediatrics
.......................................................................................................................
4
1.2
Geriatrics
.......................................................................................................................
4
2
CONTRAINDICATIONS
......................................................................................................
4
4
DOSAGE AND ADMINISTRATION
......................................................................................
5
4.1
Dosing Considerations
..................................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
............................................................. 5
4.4
Administration
..............................................................................................................
6
4.5
Mis